Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Blood (2024) 144 (Supplement 1): 889.

https://doi.org/10.1182/blood-2024-202995

Published: 2024

Journal Articles

Bone Marrow-Free Sequencing of M Protein Genes: A Liquid Biopsy Approach in Monoclonal Gammopathies

Alice Nevone, Arian Sadeghi, Giulia Mazzini, Paolo Milani, Silvia Mangiacavalli, Serena Caminito, Francesca Lattarulo, Monica Russo, Giada Panno, Marco Basset, Claudio Salvatore Cartia, Pietro Benvenuti, Martina Nanci, Claudia Bellofiore, Andrea Foli, Giampaolo Merlini, Luca Arcaini, Giovanni O. Palladini, Mario Nuvolone

Blood (2024) 144 (Supplement 1): 6905.

https://doi.org/10.1182/blood-2024-206861

Published: 2024

Journal Articles

Daratumumab-Based Regimens Versus Cybord in Newly Diagnosed Patients with AL Amyloidosis and IIIb Cardiac Stage: A Matched Case-Control Study

Claudia Bellofiore, Marco Basset, Pietro Benvenuti, Mario Nuvolone, Andrea Foli, Martina Nanci, Gianluigi Guida, Andrea Attanasio, Giampaolo Merlini, Giovanni Palladini, Paolo Milani

Blood (2023) 142 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2023-184681

Published: 2023

Journal Articles

Bone Marrow-Free Sequencing of M Protein Genes in Monoclonal Gammopathies

Alice Nevone, Giulia Mazzini, Paolo Milani, Silvia Mangiacavalli, Anna Melati, Giulia Scanavino, Maria Girelli, Serena Caminito, Marco Basset, Claudio Salvatore Cartia, Pietro Benvenuti, Martina Nanci, Claudia Bellofiore, Andrea Foli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini, Mario Nuvolone

Blood (2022) 140 (Supplement 1): 12431–12433.

https://doi.org/10.1182/blood-2022-168615

Published: 2022

Journal Articles

Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Paolo Milani, Claudia Bellofiore, Marco Basset, Andrea Foli, Pietro Benvenuti, Francesca Fabris, Martina Nanci, Mario Nuvolone, Giampaolo Merlini, Giovanni Palladini

Blood (2022) 140 (Supplement 1): 7172–7173.

https://doi.org/10.1182/blood-2022-169614

Published: 2022

Journal Articles

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival

Marco Basset, Paolo Milani, Andrea Foli, Mario Nuvolone, Pietro Benvenuti, Martina Nanci, Francesca Fabris, Claudia Bellofiore, Giampaolo Merlini, Giovanni Palladini

Blood (2022) 140 (18): 1964–1971.

https://doi.org/10.1182/blood.2022016348

Published: 2022

Includes: Supplemental data

Journal Articles

Single Molecule Real-Time Sequencing of the M Protein (SMaRT M-Seq): Toward Personalized Medicine Approaches in Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 2673.

https://doi.org/10.1182/blood-2021-147227

Published: 2021

Journal Articles

Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Marco Basset, MD, Christoph Kimmich, Tobias Dittrich, MD, Kaya Veelken, MD, Hartmut Goldschmidt, MD, Dirk Hose, MD, Anja Seckinger, MD, Anna Jauch, Carsten Mueller-Tidow, MD, Ute Hegenbart, MD, Stefan Schönland, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142701

Published: 2020

Journal Articles

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Marco Basset, Irene Defrancesco, Paolo Milani, Mario Nuvolone, Sara Rattotti, Andrea Foli, Silvia Mangiacavalli, Marzia Varettoni, Pietro Benvenuti, Claudio Salvatore Cartia, Marco Paulli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini

Blood (2020) 135 (4): 293–296.

https://doi.org/10.1182/blood.2019002762

Published: 2020

Journal Articles

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Paolo Milani, MD PhD, Francesca Fazio, MD, Marco Basset, MD, Tamara Berno, MD, Alessandra Larocca, Andrea Foli, MD, Marcello Riva, MD, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, MD PhD, Maria Teresa Petrucci, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1860.

https://doi.org/10.1182/blood-2019-130675

Published: 2019

Journal Articles

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Paolo Milani, MD PhD, Marco Basset, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1901.

https://doi.org/10.1182/blood-2019-130378

Published: 2019

Journal Articles

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Marco Basset, MD, Paolo Milani, MD PhD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 3312.

https://doi.org/10.1182/blood-2019-130364

Published: 2019

Journal Articles

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

Masayoshi Tasaki, Paolo Milani, Andrea Foli, Laura Verga, Laura Obici, Marco Basset, Margherita Bozzola, Giovanni Ferraro, Mario Nuvolone, Patrizia Morbini, Gianluca Capello, Mitsuharu Ueda, Konen Obayashi, Marco Paulli, Yukio Ando, Giampaolo Merlini, Giovanni Palladini, Francesca Lavatelli

Blood (2019) 134 (3): 320–323.

https://doi.org/10.1182/blood.2019000420

Published: 2019

Journal Articles

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Paolo Milani, MD, Faye Sharpley, Stefan Schönland, Marco Basset, MD, Shameem Mahmood, Christoph Kimmich, Andrea Foli, MD, Sajitha Sachchithanantham, Giampaolo Merlini, MD, Ashutosh D. Wechalekar, Giovanni Palladini, MD PhD, Ute Hegenbart

Blood (2018) 132 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2018-99-118034

Published: 2018

Journal Articles

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Marco Basset, MD, Irene Defrancesco, MD, Paolo Milani, MD, Sara Rattotti, MD, Andrea Foli, MD, Marzia Varettoni, MD, Alessandro Corso, MD, Marco Paulli, Giampaolo Merlini, MD, Luca Arcaini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2018-99-118161

Published: 2018

Journal Articles

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Paolo Milani, MD, Marco Basset, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2018-99-118108

Published: 2018

Journal Articles

Treatment of AL amyloidosis with bendamustine: a study of 122 patients

Paolo Milani, Stefan Schönland, Giampaolo Merlini, Christoph Kimmich, Andrea Foli, Tobias Dittrich, Marco Basset, Carsten Müller-Tidow, Tilmann Bochtler, Giovanni Palladini, Ute Hegenbart

Blood (2018) 132 (18): 1988–1991.

https://doi.org/10.1182/blood-2018-04-845396

Published: 2018

Includes: Supplemental data

Journal Articles

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Efstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, Paolo Milani, Evangelos Terpos, Marco Basset, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Dimitrios C. Ziogas, Elektra Papadopoulou, Constantinos Pamboucas, Meletios A. Dimopoulos, Giovanni Palladini

Blood (2018) 131 (14): 1568–1575.

https://doi.org/10.1182/blood-2017-12-819904

Published: 2018

Includes: Supplemental data

Journal Articles

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies

Giovanni Palladini, Paolo Milani, Andrea Foli, Marco Basset, Francesca Russo, Stefano Perlini, Giampaolo Merlini

Blood (2018) 131 (5): 525–532.

https://doi.org/10.1182/blood-2017-04-780544

Published: 2018

Includes: Supplemental data

Journal Articles

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Giovanni Palladini, MDPhD, Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 4346.

https://doi.org/10.1182/blood.V130.Suppl_1.4346.4346

Published: 2017

NARROW

Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Bone Marrow-Free Sequencing of M Protein Genes: A Liquid Biopsy Approach in Monoclonal Gammopathies

Daratumumab-Based Regimens Versus Cybord in Newly Diagnosed Patients with AL Amyloidosis and IIIb Cardiac Stage: A Matched Case-Control Study

Bone Marrow-Free Sequencing of M Protein Genes in Monoclonal Gammopathies

Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival

Single Molecule Real-Time Sequencing of the M Protein (SMaRT M-Seq): Toward Personalized Medicine Approaches in Monoclonal Gammopathies

Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Treatment of AL amyloidosis with bendamustine: a study of 122 patients

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only